Lurbinectedin not checked
Jazz Pharmaceuticals · JZP712
FollowEvery change as it happens, and a Monday email
Trials
5 active
9 in total · 5 in the EU
What this is
- How it works
- Alkylating Drug FDA class
- How it’s given
- “Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)”In the company’s words, NCT06496048 on ClinicalTrials.gov
- Tested for
- Relapsed Small Cell Lung Cancer, Leiomyosarcoma, Extensive-stage Small-cell Lung Cancer, Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
- Main trialPhase 3
- “Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined therapy versus Topotecan comparator in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.”In the company’s words, NCT06496048 on ClinicalTrials.gov
- Other names
- JZP712 · Zepzelca
Other drugs for Relapsed Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up4
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 4 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
- 30 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | |
| Phase 3Active, not recruiting | 30 Aug 2029 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | |
| Phase 2Recruiting | 4 Aug 2029 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | |
| Phase 1/2Recruiting | 28 Jan 2028 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | |
| Phase 2Terminated | 20 Dec 2023 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | |
| Phase 1/2Ended | not given | Phase I-II Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy. LiDer trial | |
| Phase 1/2Ended | not given | “Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study).” | |
| Phase 1/2Ended | not given | Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy | |
| Phase 2Authorised | not given | Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026